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Stroke is a leading cause of death and disability due to disturbance of blood supply to the brain. As brain is highly
sensitive to hypoxia, insufficient oxygen supply is a critical event contributing to ischemic brain injury. Normobaric
hyperoxia (NBO) that aims to enhance oxygen delivery to hypoxic tissues has long been considered as a logical
neuroprotective therapy for ischemic stroke. To date, many possible mechanisms have been reported to elucidate
NBO’s neuroprotection, such as improving tissue oxygenation, increasing cerebral blood flow, reducing oxidative
stress and protecting the blood brain barrier. As ischemic stroke triggers a battery of damaging events, combining
NBO with other agents or treatments that target multiple mechanisms of injury may achieve better outcome than
individual treatment alone. More importantly, time loss is brain loss in acute cerebral ischemia. NBO can be a rapid
therapy to attenuate or slow down the evolution of ischemic tissues towards necrosis and therefore “buy time” for
reperfusion therapies. This article summarizes the current literatures on NBO as a simple, widely accessible, and
potentially cost-effective therapeutic strategy for treatment of acute ischemic stroke.
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Stroke is a leading cause of death and disability. Acute
ischemic stroke results in heterogeneous changes in
cerebral blood flow (CBF) and brain metabolism in the
affected region [1]. As brain is extremely sensitive to
hypoxia, insufficient oxygen supply due to disturbance
in the cerebral blood supply is a critical event in the
pathophysiology of ischemic stroke. Therefore, oxygen
therapy that aims at improving tissue oxygen supply has
long been considered as a logical treatment for ischemic
stroke [2]. Recent animal studies have shown that short
duration of normobaric hyperoxia (NBO) treatment is
highly neuroprotective if started early after stroke onset
[3-5]. As time loss is brain loss in the setting of acute
cerebral ischemia, NBO can be administered as an early
treatment to attenuate or slow down the evolution of is-
chemic tissue towards necrosis, and thus “buy time” for
combination therapies with other neuroprotectants to
achieve better outcomes [6,7]. In this review, we will* Correspondence: kliu@salud.unm.edu
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reproduction in any medium, provided the orsummarize the current literatures on the neuroprotec-
tive studies of NBO alone and its combination with
other therapies in acute ischemic stroke.NBO-afforded neuroprotection in stroke
NBO: an ideal therapy for acute ischemic stroke
Oxygen, a commonly used therapeutic agent, has several
properties that make it an “ideal” neuroprotective drug
[8,9]. Firstly, as a small hydrophobic molecule, oxygen
can easily diffuse across the blood brain barrier (BBB) to
improve oxygen supply to brain tissue [10]. Secondly,
short durations of oxygen are relatively safe, well toler-
ated, and without dose-limiting side-effects except in
acute flare patients with chronic obstructive pulmonary
diseases [11]. Thirdly, NBO is widely available and com-
monly prescribed by medical staff in a broad range of
conditions to relieve or prevent tissue hypoxia. NBO can
be simply administered by paramedics or even at home,
which makes it an ideal acute stroke therapy. Increasing
evidence from animal stroke studies has shown that
NBO can reduce ischemic brain injury and improve
functional outcome [12-18]. Moreover, human studies
also demonstrate that NBO is associated with a transient
improvement of clinical deficits and magnetic resonanceThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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chemic stroke [19-21]. The neuroprotection of NBO are
explained by many possible mechanisms, such as im-
proving metabolism, increasing CBF, reducing oxidative
stress, and protecting microvasculature.
NBO improves tissue oxygenation and metabolism in the
ischemic brain
Hypoxia is a critical event leading to neuronal death
in stroke. Acute ischemic stroke results in heteroge-
neous changes in tissue oxygenation, with a moderately
reduced blood flow in the penumbra and a severely
hypoperfused core [1]. Using electron paramagnetic
resonance oximetry to measure localized interstitial
partial oxygen (pO2) in a rat model, Liu et al. reported
that interstitial pO2 rapidly decreased to about 30% of
pre-ischemic values in penumbra and 4% in the core
during cerebral ischemia [22]. They further showed
that 95% normobaric oxygen given during ischemia
was able to maintain penumbral interstitial pO2 levels
close to the pre-ischemic value while it caused a two-
fold increase in penumbral pO2 level if given during
reperfusion [13].
However, whether NBO improves tissue oxygenation
in stroke patients is still unkown. In light of studies on
patients with traumatic brain injury that NBO increases
brain tissue oxygen levels [23], primate or clinical studies
are needed to explore brain tissue oxygenation in stroke
during NBO therapy.
Abnormal metabolism is another major cause of brain
injury under ischemic/hypoxic condition. NBO has been
shown to reduce tissue acidosis and ATP depletion in
the border zones of focal cerebral ischemia [24]. Multi-
voxel magnetic resonance spectroscopic imaging from
stroke patients with inhalation oxygen in a flow of 45 L/
min through a face mask for 8 hours indicated that lac-
tate (a marker for aerobic metabolism) decreased during
NBO administration, suggesting that NBO improves aer-
obic metabolism in stroke patients [21]. As the penum-
bra is the region that can potentially be rescued if blood
flow is restored in time [25], NBO may work as an early
intervention to preserve the penumbra and expand the
time window of reperfusion therapies.
Inspired by recent reports on postconditioning with
intermittent occlusions of cerebral artery, Liu et al. re-
cently showed that intermittent NBO treatment (4 short
cycles of intermittent NBO/air treatment) provided similar
neuroprotection at 24 hours after ischemia onset and even
greater neuroprotection at 72 hours, when compared to
continuous NBO [26]. Their results suggest that besides
providing oxygen to the ischemic tissue, intermittent
NBO must have exerted its neuroprotection through other
mechanisms. It is conceivable that intermittent NBO may
trigger a novel form of postconditioning, in which theobserved neuroprotection may be mediated by attenuating
superoxide generation and activation of the Akt pathway.
These findings suggest that, in addition to improving oxy-
gen supply and metabolism, NBO could induce endogen-
ous protective mechanisms to reduce ischemic brain injury.
Changes in cerebral blood flow
It is well accepted that healthy tissue responds to hyper-
oxia with consistent vasoconstriction [27]. How the CBF
changes in ischemic tissue in response to NBO therapy
is an important question. An early study from Liu et al.
showed that NBO given during cerebral ischemia
increased CBF in the ischemic penumbra, which was ac-
companied by a reduction in CBF in the contralateral
hemisphere [13]. When NBO was delivered during
reperfusion, it significantly decreased penumbral CBF.
The blood flow in the core region was not affected by
NBO during both ischemia and reperfusion [13]. Using
real-time two-dimensional multispectral reflectance im-
aging and laser speckle flowmetry, Shin et al. reported
that NBO significantly increased the CBF in ischemic
cortex and reduced the cortical infarction in comparison
to room air 1 hour after middle cerebral artery occlusion
(MCAO) onset [28]. A study using functional cerebral
blood volume (fCBV) also showed that contralateral
healthy tissue responded consistently with vasoconstric-
tion (fCBV reduction), while tissue from ischemic core
showed marginal fCBV changes that later became mod-
erate fCBV reductions. As for penumbra tissue, it
showed relative preservation of mean fCBV at early time
points, later exhibited significantly decreased fCBV
(vasoconstriction) like healthy tissue [16].
The study from Henninger et al. indicated that NBO
acutely preserved the perfusion/diffusion mismatch
without altering CBF, because CBF characteristics and
CBF-derived lesion volumes did not differ between
NBO-treated and untreated animals [12]. The authors
explained that the observed mild elevation of PaCO2
may have counterbalanced the vasoconstrictive effects
associated with hyperoxia, suggesting that CBF changes
were unlikely to be a major mechanism of neuroprotec-
tion in the acute phase of ischemia in this model.
Taken together, change of CBF in ischemic tissue in
response to NBO is complicated, and whether CBF aug-
mentation would eventually benefit stroke animals or
patients needs to be investigated further.
Impact on oxidative stress
Reactive oxygen species (ROS) may be generated when tis-
sue oxygen level is too high or too low [29]. Oxidative stress
has been widely considered as one of important mechan-
isms in ischemic and/or reperfusion injury [30,31]. Evidence
from recent animal studies has demonstrated that short
duration of NBO treatment does not increase oxidative
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cated that recirculation following brief periods of ischemia
(15 min) did not lead to an enhanced H2O2 production
with the aminotriazole/catalase method, and that hyperoxia
did not aggravate the ischemic damage [32]. Liu et al. have
shown that NBO given during cerebral ischemia reduces
superoxide production and the generation of 8-OHdG, a
biomarker of oxidative DNA damage [13]. In an attempt to
identify the underlying mechanism, Liu et al. found that
NBO inhibited the upregulation of gp91phox, the catalytic
subunit of NADPH oxidase [33]. In addition, when
gp91phox was knocked out in the transgenic mouse model,
NBO was no longer able to induce reduction in BBB leak-
age [14]. These results are further supported by the report
that NBO treatment during focal cerebral ischemia-
reperfusion does not increase oxidative stress, as measured
by heme oxygenase-1 induction and protein carbonyl for-
mation [34]. Findings from these studies indicate that NBO
treatment decreases ROS production in the penumbra
when penumbral pO2 is maintained close to the pre-
ischemic level.
The effect of NBO on reactive nitrogen species (RNS)
generation has also been examined in an animal stroke
model. Yuan et al. recently showed NBO given during cere-
bral ischemia delayed and attenuated early nitric oxide gen-
eration, probably through inhibiting neuronal nitric oxide
synthase (nNOS) [35]. In this study, they found that ische-
mia caused rapid production of NOx
− (nitrite plus nitrate),
with a peak at 10 min after stroke onset, then gradually de-
clining to the baseline level at 60 min. NBO delayed the
NOx
− peak to 30 min and attenuated the total amount of
NOx
−. Moreover, NBO showed similar inhibitory effect on
NOx
− and 3-nitrotyrosine production as that of the specific
nNOS inhibitor 7-nitroindazole.
Together, these studies suggest that, contrary to common
belief, under appropriate conditions NBO treatment would
not cause observable increase of oxidative stress, while it
may actually decrease oxidative stress in the penumbra.
However, the underlying mechanism is not fully under-
stood, and will require further investigation.
The findings from the studies on oxidative stress also
suggest that the brain is more tolerable to hyperoxia than
hypoxia. Although NBO treatment elevates tissue pO2 in
the contralateral brain to a level that is much higher than
the physiologic value, it did not increase ROS production
[13]. Furthermore, when 95% oxygen was delivered during
reperfusion, penumbral pO2 level was twice of the preis-
chemic level, however no significant increase in ROS gener-
ation was observed [13]. These findings may be explained
by different CBF responses to NBO in healthy, penumbral
and core tissues [16]. Vasoconstriction is the normal func-
tion for healthy vasculature to avoid oxygen overload and
the risk of oxidative stress. As for ischemic tissue, loss of
functional vasoconstriction (vasodilation) in response tohyperoxia fortunately increases CBV and oxygen supply to
overcome hypoxia. Once the tissue is rescued, the func-
tional vasoconstriction may also return to avoid excessive
oxygen supply.
Protection on blood brain barrier
Blood brain barrier (BBB) is a physical and metabolic
diffusion barrier between cerebral microvessels and the
surrounding tissue, which is essential for the mainten-
ance of homeostasis and the normal function of the cen-
tral nervous system [2,36]. Matrix metalloproteinases
(MMPs) have been the focus of many studies of cerebral
ischemia because of their substrate specificity for fibro-
nectin, laminin, collagen type IV and tight junction pro-
teins (TJPs), which are structural components of the
BBB [37].
In stroke animal models, the activity or expression of
MMP-2 and −9 is significantly increased, which is closely
related to BBB disruption, edema formation and intracranial
hemorrhage [38-45]. Evidence from animal stroke studies
shows that NBO inhibits MMP-9 induction in the ischemic
brain, leading to reduction in occludin degradation, Evan’s
blue extravasation and hemispheric swelling [3,13,33]. The
mechanism by which NBO suppresses MMP-9 and attenu-
ates BBB damage appears to involve NADPH oxidase, be-
cause i) inhibition of NADPH oxidase with apocynin or
knockout of gp91phox resulted in much smaller magnitudes
in MMP-9 induction and BBB leakage in the ischemic brain
[13,14,33], and ii) NBO did not cause additional reduction
in MMP-9 induction when gp91phox was knocked out [14].
These results indicate that inhibition of NADPH oxidase-
derived ROS production may be an important mechanism
underlying NBO-afforded BBB protection. As the tightness
of the BBB is crucial to ensure the ischemic brain to safely
withstand the return of blood flow, early treatment with
NBO may “buy time” for thrombolytic therapy by attenuat-
ing or slowing down the disruption of the BBB.
Controversies in NBO protection
Although a large pool of evidence has demonstrated that
NBO is beneficial if it is given during cerebral ischemia,
there are also controversial reports. For example, Li et al.
reported that they failed to see a significant decrease in
the infarct size [46]. In another study, NBO therapy for a
24 hour period was shown to reduce brain swelling in
MCAO rats, but had no effect on brain infarction [46].
Perhaps, NBO for extended time (e.g., 24 hour) might re-
duce its neuroprotective effect. In an attempt to explore
the long-term effect of NBO on ischemic brain injury,
Mickel et al. showed that NBO resulted in a more severe
damage to myelin sheaths in gerbils that survived 28 days
after stroke onset, although neurons in the deeper laminae
of the cerebral cortex appeared to be better preserved in
these animals [47].
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stroke studies regarding to NBO’s neuroprotection. Singhal
et al. reported that NBO therapy via facemask for 8 hours
improves stroke scale scores at 24 hours in NBO-treated
patients, but not at 3 months [20]. In addition, mean rela-
tive diffusion MRI lesion volumes were also significantly
reduced in NBO-treated patients at 4 hours but not subse-
quent time points. These findings indicated that NBO’s
effects might be transient. Another study by Chiu et al.
showed that breathing 40% oxygen using venturi mask
decreased mortality and comorbidities in patients experi-
encing a first-ever large MCA infarction (more than one
third of the MCA territory on brain images) within
48 hours [19]. On the contrary, Padma et al. reported that
NBO in a flow of 2 L/min failed to improve the clinical
scores of mean National Institute of Health stroke scale
(NIHSS), modified Rankin score, Barthel index at 0, 1,
7 day of admission and at 3 months follow-up in stroke
patients [48]. Obviously, better-designed clinical studies
with well defined patient groups (e.g., the optimum con-
centration of oxygen inhalation and time after stroke
onset) are needed to further investigate the safety and effi-
cacy of NBO as a stroke therapy.Combination treatment with NBO
The Stroke Therapy Academic Industry Roundtable
(STAIR) has strongly recommended the use of multiple
neuroprotective therapies for treating stroke, in which
each agent that works on a different ischemic injury
mechanism could be given either simultaneously or in
rapid succession [49,50]. As NBO is widely available and
can be promptly initiated after stroke onset, NBO may
be an ideal early stroke treatment to preserve the ische-
mic penumbra, and then followed by treatment withFigure 1 The schematic diagram of neuroprotection of NBO alone orother neuroprotectants to eventually salvage the ische-
mic penumbral tissue.
NBO plus tPA thrombolysis
A major goal in the treatment of acute ischemic stroke
is prompt arterial recanalization. Until now, thromboly-
sis with tissue-type plasminogen activator (tPA) within 3
or 4.5 hour after symptom onset is the only FDA-
approved treatment for acute ischemic stroke. Delayed
thrombolytic therapy dramatically increases the risk of
intracranial hemorrhage (ICH) [51]. As a fact, the brief
therapeutic window and the high incidence of ICH have
profoundly constrained the clinical use of tPA in ische-
mic stroke patients. Therefore, combination strategies
that address not only tPA-associated ICH and its narrow
therapeutic window, but also limit ischemic damage
[49], are urgently needed.
Although the mechanisms underlying tPA-induced
ICH are not fully understood, it has been suggested that
ICH occurs as a result of BBB disruption by enhancing
the proteolytic activity, such as MMPs [52-56]. Several
human studies have also demonstrated that stroke
patients with higher pretreatment plasma level of MMP-
9 or its substrate are more likely to undergo cerebral
hemorrhagic complications after tPA [57,58].
Since NBO can effectively limit ischemic neuronal
death, as well as reduce BBB disruption in animal
experiments [14,34], it is logic to speculate that NBO
could serve as a promising adjunctive therapy to reduce
tPA-associated ICH and widen the thrombolysis window
in stroke. The potential for combined NBO treatment
with tPA thrombolysis was recognized several years
ago [15,59]. Henninger et al. showed that the combin-
ation of NBO with tPA did not increase hemorrhage vol-
ume at 10 hours or occurrence of confluent petechialcombination therapy in ischemic stroke.
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[60]. NBO also did not increase cellular markers of
superoxide generation or brain levels of MMP-9 [61].
These data provides important initial evidence to support
the combination therapy with NBO and tPA in ischemic
stroke.
It was reported that combined NBO and tPA signifi-
cantly reduced the mortality rate (from 70% to 11% in
tPA-treated rats), brain edema, hemorrhage, and MMP-9
augmentation in a filament occlusion rat model with 5-
hour ischemia followed by 19-hour reperfusion, as com-
pared with tPA alone [6]. The authors also pointed out
that they could not draw a solid conclusion on the
causal relationship between mortality and cerebral
hemorrhage, as they did not measure hemorrhage vol-
ume for those rats that died prematurely during reperfu-
sion, most of which were tPA-treated normoxic rats.
Nevertheless, their findings indicate that NBO can in-
crease the safety of delayed tPA treatment. However, dif-
ferent results have also been reported, in which Fujiwara
et al. showed that NBO plus tPA did not significantly
alter hemorrhagic conversion, brain swelling, or mortal-
ity at 24 hours, as compared with tPA alone in an em-
bolic MCAO model stroke [62]. The discrepancy might
be derived from the difference in stability of animal
models. Apparently, further investigation is needed to
ascertain the safety and efficacy of delayed tPA treat-
ment combined with NBO before application in human
stroke patients.
NBO plus other therapies
Minocycline, a tetracycline antibiotic, possesses proper-
ties against reperfusion injury, including anti-inflamma-
tory, anti-apoptotic, and BBB protection. Jin et al.
reported that NBO therapy after ischemia onset plus
minocycline intravenous injection after reperfusion onset
provides greater reduction in infarct size and edema vol-
ume. NBO plus minocycline also effectively reduces
brain injury due to its inhibition on MMP-2/9-mediated
occludin degradation and the activation of caspases and
apoptosis inducing factor [63].
Effects of combination treatment with NBO and edar-
avone, a potent scavenger of hydroxyl radicals (intraven-
ously injected after ischemia), were evaluated for
reducing acute brain injury in a 2-hour filament ische-
mic mouse model [64]. This study indicated that com-
bination group showed smaller infarct volume, better
neurological functions and less TUNEL-positive cells in
the ischemic boundary zone both in cortex and subcor-
tex at 22 hours after reperfusion than the two monother-
apy groups, suggesting that combination therapy with
NBO plus edaravone prevented the neuronal damage
after focal cerebral ischemia and reperfusion in mice.
Combination therapy with NBO plus cilostazol, aselective inhibitor of phosphodiesterase-3, was also
proved to protect the mice subjected to focal cerebral is-
chemia by improving CBF after reperfusion, which was
partially attributed to endothelial nitric-oxide synthase
activity [65].
NBO has also been suggested to combine with ultra-
sound and tPA in acute ischemic stroke [66]. Enhanced
dissolved oxygen secondary to NBO treatment increases
gas nuclei formation around and inside of the clot.
Under ultrasound field, these small gas nuclei form nano
bubbles that fuel inertial cavitation as substrates, and
therefore increase the clot fragmentation and lysis.
Since multiple mechanisms contribute to ischemic in-
jury, it is logic and appropriate to consider the “cocktail”
approach to intervene multiple mechanisms. Moreover,
combined therapies are also helpful for reducing the
dosage and minimizing the toxicity of individual agent.
Conclusions
At present, stroke patients receive variable amounts of
oxygen in the ambulance and current guidelines do not
support the routine use of in-hospital oxygen [67,68]. In
light of the positive preclinical and clinical reports, fur-
ther studies are warranted to explore the efficacy of
NBO therapy alone or in combination with other neuro-
protectants for treatment of acute ischemic stroke, and
to determine the optimum timing and duration of the
therapy. NBO, a simple, widely accessible and potentially
cost-effective therapeutic strategy could significantly im-
prove the clinical outcome of stroke patients if used ap-
propriately (Figure 1).
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